You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 9, 2026

Court Judgment Reaffirms Rules on Advertising of Medical Facilities in Thailand

On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars.

The plaintiff brought a claim against both the physician-owner and the clinic company, alleging that the advertisements were false and induced her to purchase the treatment. The court found that the clinic was liable for the false representations and that the physician-owner, as both the authorized director of the company and the medical practitioner who provided treatment, was jointly responsible.

Although the plaintiff could not fully prove all damages claimed, the court awarded compensation of THB 20,000, together with interest.

While the judgment arose from a consumer protection dispute, it serves as a valuable reminder that medical facility advertisements in Thailand are regulated and may expose clinics and healthcare providers not only to regulatory enforcement but also to civil liability from patients who rely on misleading promotional claims.

Regulatory Framework Governing Medical Facility Advertisements

Medical facility advertising in Thailand is governed by the Medical Facility Act B.E. 2541 (1998), as amended by the Medical Facility Act (No. 4) B.E. 2559 (2016).

The principal secondary legislation is the Department of Health Service Support (DoHSS) Notification Re: Rules, Procedures, Conditions, and Fees for an Advertisement or Publication Concerning a Medical Facility, which came into force on November 25, 2019. Under this notification, “advertising” includes any act, by any means, that causes members of the public to see, hear, or otherwise become aware of a message, sound, or image for the commercial benefit of a medical facility. This broad definition covers not only traditional media but also clinic websites, social media, and other digital marketing channels.

Prior Approval Requirement

Section 38 of the Medical Facility Act requires medical facilities to obtain approval from the DoHSS before publishing any advertisement relating to the facility.

The only statutory exception is where the communication contains solely the medical facility’s name and location exactly as stated in its license.

Section 38 also expressly prohibits advertisements containing false, exaggerated, deceptive, or misleading statements—regarding the medical facility’s name or location, the medical services offered, the qualifications of healthcare professionals, or the competence or capabilities of healthcare personnel—that are intended to induce individuals to use the facility’s services.

The recent acne scar treatment case demonstrates the risk associated with claims that promise specific results, represent a doctor as possessing special expertise without adequate substantiation, or suggest that a treatment can permanently cure a condition.

Advertisements Exempt from Prior Approval

The 2019 notification permits certain information to be displayed within the medical facility premises without obtaining prior approval, including:

  • Abbreviations, trade names, logos, and symbols
  • Qualifications of healthcare professionals
  • Service fees and pricing information
  • Patient rights information
  • Lists of medical services and operating hours
  • Medical and public health knowledge, research findings, and educational content (subject to prescribed warning statements)
  • Announcements concerning facility activities, relocation, destruction of records, or commemorative events

Advertisements That May Be Approved

Advertisements outside the exemption categories require approval before publication. The DoHSS may approve advertisements that contain the following promotional elements, provided specific conditions are met:

  • Free medical services. Advertisements promoting free services must clearly state the date and time, the location, and the scope of the services offered.
  • Gifts, exchanges, benefits, prizes, or lucky draws. These may be offered only if the service recipient is the direct beneficiary and the medical service provided is not below the general standard.
  • Discounts on non-medical services. These may be offered only if the service recipient is the direct beneficiary.
  • Discounts on medical services. These may be offered for a period of up to one year.

Application Procedures

The approval process depends on the location of the medical facility.

  • For facilities located in Bangkok, applications must be submitted to the Center of Healthcare Advertising Approval (CHAA) within the DoHSS. Applications may be filed in person or by post. According to the CHAA website, straightforward applications involving text or still images may be approved within approximately five to seven working days after complete documentation is submitted.
  • For facilities located outside Bangkok, applications must be submitted to the relevant Provincial Public Health Office.

Penalties for Noncompliance

Failure to obtain prior approval may result in a fine of up to THB 20,000 and an additional daily fine of up to THB 10,000 for failure to comply with an order requiring the advertisement to be removed.

Advertisements that are false, exaggerated, deceptive, or misleading carry more severe penalties: imprisonment of up to one year, a fine of up to THB 20,000, or both. Additional daily fines of up to THB 10,000 may also be imposed until the offending advertisement is withdrawn.

Increased Enforcement Against Repeat Offenders

According to recent statements from the DoHSS, enforcement against repeat offenders is becoming increasingly stringent. The department reportedly applies an escalating penalty approach:

  • First violation: approximately 25 percent of the maximum fine
  • Second violation: approximately 50 percent
  • Third violation: approximately 75 percent
  • Fourth violation: referral for criminal prosecution

Importantly, the authority currently considers each advertising platform separately. In other words, violations are generally assessed by channel rather than by the number of individual posts. However, authorities have indicated that future enforcement may consider each prohibited claim separately, potentially increasing exposure significantly, including the risk that serious or repeated violations may give rise not only to civil claims but also to criminal complaints or prosecution.

The DoHSS is also reportedly considering introducing informer reward mechanisms for advertising violations, although the proposal remains under review. If adopted, such mechanisms could further increase the likelihood of complaints being filed, including potential criminal complaints in cases involving false, exaggerated, deceptive, or misleading advertising.

As enforcement activity continues to increase, the distinction between aggressive marketing and unlawful advertising is becoming increasingly important. A misleading claim may not only result in regulatory penalties but may also expose the clinic, its directors, and treating healthcare professionals to civil claims from dissatisfied patients and, where the facts support it, to criminal complaints or prosecution under the applicable statutory framework.

RELATED INSIGHTS​ 

February 26, 2026
Laos’ Food and Drug Department (FDD) has been using a new online registration system for drugs since the beginning of the year. The system, which was implemented following the November 2025 issuance of Notice No. 5960/FDD, became the official pathway for submissions on January 1, 2026. Since that date, paper-based registrations have no longer been accepted. This marks a significant advancement in the digitalization of regulatory processes in Laos. As the online system is now the exclusive platform for registration, renewal, and amendments, companies that have not yet aligned their processes to the new system should act promptly to ensure a smooth transition. To assist with this, the FDD will conduct periodic training sessions on the use of the online registration system, which will be delivered either in person or remotely, depending on operator demand. To start using the system, drug and medical device manufacturers, as well as import-export companies, that have not yet registered must submit a formal request identifying the authorized personnel who will access the platform, after which they will be issued user accounts and access codes. Each request must be accompanied by the company’s enterprise registration certificate (incorporation certificate), a copy of the identity card or passport of each designated user, and a scanned copy of their signature. There is no restriction on the number of users per company, allowing flexibility to meet operational needs. Companies that already hold accounts and access codes from the trial phase may continue using them and may apply for additional accounts if needed. Additional Requirements The new system also introduces a standardized format for drug registration numbers. For example, an import drug registration number such as 06 I 4040/15 will be changed to 06-IM-04040-15, and a domestic drug registration number such as 06 L 4040/15 will be changed to
January 21, 2026
Spurred by global geopolitics and Canada’s Indo-Pacific Strategy, which aims to forge deeper ties with ASEAN, Canadian companies have been showing growing interest in Thailand and Southeast Asia in recent years. To understand the opportunities offered by the region, we sat down with Andrew Stoutley, a Toronto native and the chief operating officer of Tilleke & Gibbins, a leading Southeast Asian regional law firm with over 130 years of history in Thailand. Q: Why are Canadian companies looking at Thailand and Southeast Asia right now? A: Two reasons stand out. First, diversification has moved up the agenda. Many Canadian companies want options outside North America due to tariff volatility and policy uncertainty in the United States, as well as questions around the next Canada–United States–Mexico Agreement mandatory joint review. At the same time, the shift of global production from China to Southeast Asia is accelerating, driven by rising costs, geopolitics, and the need to avoid overreliance on a single market. As a result, Canadian companies are looking for a second production base or a regional hub, and Thailand and its neighbors are natural choices given their manufacturing depth, location, and established supply chains. Second, Canada’s own efforts in the region are gaining traction. The Indo-Pacific Strategy has led to more on-the-ground support, including larger trade missions, upgraded diplomatic posts, and new financing options. Export Development Canada (EDC) now has a presence in Bangkok, giving Canadian companies a direct line to financing and insurance in Thailand. There’s also steady progress on trade frameworks like the recently signed Canada–Indonesia Comprehensive Economic Partnership Agreement (which will come into effect pending domestic procedures), ongoing negotiations of a Canada–ASEAN FTA, and the exciting announcement about the launch of negotiations of a Canada–Thailand FTA. Together, these developments have the potential to make it much easier
January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
January 6, 2026
On December 30, 2025, Thailand’s Electronic Transactions Development Agency (ETDA) notified digital marketplace operators of a consolidated list of “high‑risk products” that are subject to strict monitoring on digital platforms. The list was jointly prepared by the Thai Industrial Standards Institute (TISI) and the Food and Drug Administration (FDA) to guide platform compliance in the initial phase of implementation of the Electronic Transaction Committee’s Notification on Other Measures for Marketplace for Goods with Specific Characteristics under Section 18(2) of the 2022 Royal Decree on Digital Platform Businesses Requiring Notification B.E.2568 (2025). The notice is addressed to operators of digital platform services that function as product marketplaces with specific characteristics laid out in the notification. The ETDA states that the TISI and the FDA are closely monitoring the high‑risk product categories on digital platforms, and the published list serves as the baseline reference for platform screening during the initial phase of the notification’s implementation. High‑Risk Product List The list aggregates categories of products that are illegal to sell online or are otherwise tightly regulated under Thai law, with an emphasis on health-related products, controlled substances, medical devices, and a wide range of industrial products that require certification or compliance with specified Thai Industrial Standards, as detailed below. Prohibited and tightly controlled health products. This includes all categories of modern medicines subject to control other than general household remedies; all categories of controlled herbal products except for over-the-counter herbal products; narcotics; psychotropic substances; and medical devices requiring use in medical facilities or a physician’s prescription. Selected industrial products requiring heightened controls. The list highlights dozens of TISI-regulated items commonly sold online. Examples include pacifiers, rice cookers, electrical wire, food wrap film, crayons, washing machines and dryers, air conditioners, electric cookers and air fryers, water heaters, microwave ovens, LED luminaires, hair dryers